Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sagimet Biosciences, Inc. Class A (SGMT)
NASDAQ:SGMT
RESEARCH TOOLSreports
Holding SGMT?
Track your performance easily
SGMT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.39 - $20.71
Previous Close$4.36
Volume463.86K
Average Volume (3M)1.46M
Market Cap
$145.09M
Enterprise Value-$7.28M
Total Cash (Recent Filing)$152.49M
Total Debt (Recent Filing)$116.00K
Price to Earnings (P/E)―
Beta4.24
Next Earnings
Mar 31, 2025EPS Estimate
-$0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.29
Shares Outstanding30,674,855
10 Day Avg. Volume715,698
30 Day Avg. Volume1,460,005
Standard Deviation0.43
R-Squared0.03
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.73
Price to Sales (P/S)72.55
Price to Cash Flow (P/CF)-6.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-3.64
Enterprise Value/Gross Profit-3.64
Enterprise Value/Ebitda0.25
Forecast
1Y Price Target
$25.33Price Target Upside474.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Sagimet Biosciences, Inc. Class A News
PremiumCompany Announcements
Sagimet Biosciences Advances MASH Treatment with Denifanstat
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageDenifanstat has a highly differentiated mechanism-of-action that inhibits endogenous FASN activity directly in hepatocytes, immune cells, and stellate cells, thereby simultaneously addressing the three main drivers of liver injury.
Market PotentialThe MASH market is projected to continue growing, offering a large potential for peak sales for denifanstat.
Regulatory MilestonesDenifanstat's Phase 3 MASH program is designed for accelerated approval, indicating strong regulatory confidence.
Bears Say
Capital RequirementsManagement needs to generate capital of at least approximately $200M to complete the Phase 3 program.
Financial PerformanceSGMT reported a net loss of $14.6 million, indicating financial challenges.
Product ConcernsHair thinning adverse effects could deter some patients from using denifanstat, but these can potentially be managed with dose reductions or other strategies.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SGMT FAQ
What was Sagimet Biosciences, Inc. Class A’s price range in the past 12 months?
Sagimet Biosciences, Inc. Class A lowest stock price was $2.39 and its highest was $20.71 in the past 12 months.
What is Sagimet Biosciences, Inc. Class A’s market cap?
Currently, no data Available
When is Sagimet Biosciences, Inc. Class A’s upcoming earnings report date?
Sagimet Biosciences, Inc. Class A’s upcoming earnings report date is Mar 31, 2025 which is in 128 days.
How were Sagimet Biosciences, Inc. Class A’s earnings last quarter?
Sagimet Biosciences, Inc. Class A released its earnings results on Nov 14, 2024. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.388 by -$0.062.
Is Sagimet Biosciences, Inc. Class A overvalued?
According to Wall Street analysts Sagimet Biosciences, Inc. Class A’s price is currently Undervalued.
Does Sagimet Biosciences, Inc. Class A pay dividends?
Sagimet Biosciences, Inc. Class A does not currently pay dividends.
What is Sagimet Biosciences, Inc. Class A’s EPS estimate?
Sagimet Biosciences, Inc. Class A’s EPS estimate is -$0.56.
How many shares outstanding does Sagimet Biosciences, Inc. Class A have?
Sagimet Biosciences, Inc. Class A has 30,674,854 shares outstanding.
What happened to Sagimet Biosciences, Inc. Class A’s price movement after its last earnings report?
Sagimet Biosciences, Inc. Class A reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.388. Following the earnings report the stock price went down -13.953%.
Which hedge fund is a major shareholder of Sagimet Biosciences, Inc. Class A?
Among the largest hedge funds holding Sagimet Biosciences, Inc. Class A’s share is Baker Bros Advisors LP. It holds Sagimet Biosciences, Inc. Class A’s shares valued at 4M.
---
Sagimet Biosciences, Inc. Class A Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.33 (474.38% Upside)
$25.33 (474.38% Upside)
Blogger Sentiment
Bullish
SGMT Sentiment 66%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Neutral
Last 7 Days <0.1%
Last 30 Days >0.1%
Last 30 Days >0.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
47.29%
12-Months-Change
Fundamentals
Return on Equity
-27.94%
Trailing 12-Months
Asset Growth
69.81%
Trailing 12-Months
Company Description
Sagimet Biosciences, Inc. Class A
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
---
SGMT Stock 12 Month Forecast
Average Price Target
$25.33
▲(474.38% Upside)
Technical Analysis
Best Analysts Covering SGMT
1 Year
1 Year Success Rate
6/8 ratings generated profit
1 Year Average Return
+15.19%
assigned a buy rating 8 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +15.19% per trade.
---